Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isis Pharmacueticals

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

Roche’s Zelboraf combination to receive priority FDA review

US regulator to assess drug's use with cobimetinib for melanoma within six months

Roche Basel Switzerland

Roche taps Qualcomm for remote health monitoring

Builds on collaboration with Novartis on remote trial observation

Catabasis hires Rick Modi as its chief business officer

Will help the firm develop its flagship Duchenne muscular dystrophy product

Roche Basel Switzerland

Roche acquires cancer biobank firm Signature Diagnostics

Marks Swiss firm's fifth deal this year to expand its molecular diagnostics business

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

Roche Basel Switzerland

Roche’s newer breast cancer drugs gain traction

Perjeta and Kadcyla boost 2014 revenues

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

- PMLiVE

Former Roche CEO joins BIAL board

Franz Humer to advise Portuguese pharma company

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links